Latest News - Paratek Pharmaceuticals, Inc.

Thursday, August 09, 2018

FDA Committee Recommends Approval of Paratek’s Omadacycline

The Antimicrobials Drug Advisory Committee of the FDA voted in favor of the approval of intravenous (IV) and oral omadacycline for the treatment of acute bacterial skin and skin structure infections (…

Read the full story

Wednesday, December 20, 2017

FDA Accepts NDA for Allergan, Paratek Acne Drug

The U.S. Food and Drug Administration accepted a New Drug Application (NDA) to review SeysaraTM(sarecycline) for the treatment of moderate to severe acne vulgaris in patients 9 years of age and older,…

Read the full story